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Structure-activity relationship studies of the cyclopentapeptide CXCR4 antagonists (cyclo(-L-
/D-Arg1-Arg2-2-Nal3-Gly4-D-Tyr5-)) suggest that the L-/D-Arg1-Arg2-2-Nal3 tripeptide 
sequence contained within these cyclopentapeptides serves as a recognition motif for peptidic 
CXCR4 antagonists. Starting by dissecting the cyclopentapeptide structure and reintroducing 
cyclic constraints in a stepwise manner, we here report a novel class of scaffold-based 
tripeptidomimetic CXCR4 antagonists based on the D-Arg-Arg-2-Nal motif. Biological 
testing of the prototype compounds showed that they represent new peptidomimetic hits; 
importantly, the modular nature of the scaffold provides an interesting starting point for 










































CXC chemokine receptor 4 (CXCR4) is a peptidergic GPCR with the 68-residue peptide 
CXC chemokine ligand 12 (CXCL12) as its only endogenous ligand.1,2 In addition to the 
developmental and physiological role of CXCL12/CXCR4, CXCR4 has been shown to be 
involved in a number of pathological conditions, including HIV, cancer, and rheumatoid 
arthritis.3 Consequently, CXCR4 has emerged as an attractive drug target, and several small-
molecule CXCR4 antagonists have been described in the literature over the last decade,3,4 
including a series of cyclic pentapeptides based on the amino acid sequence L-/D-Arg1-Arg2-
2-Nal3-Gly4-D-Tyr5 (2-Nal = L-3-(2-naphthyl)alanine), i.e. the L-Arg1 epimer 1 (FC131) and 
the D-Arg1 epimer 2 (FC092) (Figure 1).5 
 
 
Figure 1. Structures of the lead cyclopentapeptide antagonists 1 and 2. 
 
Small cyclic peptides, such as cyclopentapeptides, are known to mimic peptide turns,6 i.e. 
structural motifs where the peptide backbone folds back on itself to form a pseudo-cyclic 
structure. Such turns appear to be a universal ligand recognition element for peptidergic 
GPCRs;7 thus, the cyclopentapeptide CXCR4 antagonists represent an excellent starting point 
for design of novel CXCR4 antagonists based on smaller turn-mimicking scaffolds. Such 
scaffolds have to maintain the 3D-orientation of the pharmacophoric groups of the parent 
peptide, resulting in a so-called topographical (or type-III) peptidomimetic.8 With respect to 
size, a recent review points out that three amino acids represent an optimal size for small-
molecule peptidomimetics.9 
 
The Gly4 residue in the cyclopentapeptide CXCR4 antagonists (Figure 1) was originally 
introduced for synthetic reasons5 and thus can be considered as a spacer. Through SAR 
studies, it has become clear that the D-Tyr5 side chain is not essential for biological 
activity,10,11 and we have in a recent molecular docking study found that this may stem from 

























suggested that D-Tyr5 of 1 is partly solvent exposed, the phenolic hydroxyl group was found 
to take part in hydrogen bonding to Glu32.11 However, as the D-Phe5 analogue was found to 
be only 2-fold less potent, this H-bond is not essential for antagonistic activity; indeed, the 
Gly5 analogue of 1 was found to be only one order of magnitude less potent than 1 in our 
assay system.11 Collectively, these observations imply that the remaining L-/D-Arg1-Arg2-2-
Nal3 tripeptide fragment serves as a recognition motif for peptidic CXCR4 antagonists, which 
motivates further studies of both flexible and constrained small molecules containing this 
motif. Through dissection of the cyclopentapeptide structure and a stepwise reintroduction of 
cyclic constraints, we here report the design, synthesis, and biological evaluation of a novel 
class of scaffold-based tripeptidomimetic CXCR4 antagonists based on the D-Arg-Arg-2-Nal 
motif. 
 
2. RESULTS AND DISCUSSION 
 
2.1. General Design Considerations. 
As SAR studies of the cyclopentapeptide CXCR4 antagonists (Figure 1) have demonstrated 
that position 2 (L-Arg) is very sensitive to structural modifications,12,13 we decided to keep L-
Arg2 throughout this study. Similarly, we have recently shown that replacement of L-2-Nal in 
position 3 with aromatic/alicyclic analogs results in significant reduction of the antagonistic 
potency,11 and therefore used a 2-naphthyl group with the appropriate spacer length for all 
compounds. In contrast, position 1 has been shown to be relatively tolerant to structural 
modifications, both with respect to stereochemistry (L- or D-arginine) and the chemical nature 
of the side chain.13,14 Even if the originally discovered L-Arg1 epimer 1 displays somewhat 
higher affinity than the D-Arg1 epimer 2 (Figure 1; IC50-values of 0.004 and 0.008 µM, 
respectively),5 subsequent SAR studies have shown that cyclopentapeptide analogs 
containing D-Arg1 in many cases are more active than the corresponding L-Arg1 epimers. For 
example, the most active cyclopentapeptide CXCR4 antagonist reported to date is the N-
methylated D-Arg1 epimer FC122 (cyclo(-N-Me-D-Arg1-Arg2-2-Nal3-Gly4-D-Tyr5-)), which 
showed 8-fold higher affinity than the corresponding L-Arg1 epimer (IC50-values of 0.003 
and 0.023 µM, respectively).10 Moreover, head-to-tail cyclization of peptides is known to be 
facilitated by incorporation of a D-amino acid in an all-L sequence due to a turn-inducing 
effect.15 For these reasons, we decided to focus on the D-Arg1 epimers in the present study, 
using the lead cyclopentapeptide 2 (cyclo(-D-Arg1-Arg2-2-Nal3-Gly4-D-Tyr5-), Figure 2A) as 
starting point.  
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2.2. Biological Evaluation. 
The antagonistic potency of the synthesized compounds 2–14 (Figures 2 and 6) on human 
CXCR4 was determined by a functional assay as previously described13 and is shown in 
Table 1; the EC50-value of the known lead compound 2 was 0.52 µM. 
 
Table 1. Antagonistic potency of compounds 2–14 on human CXCR4. 
Compda log EC50 ± SEMb EC50 (µM) 
2c -6.28 ± 0.09 0.52 
3 -4.24 ± 0.35 58 
4 -4.07 ± 0.24 86 
5 -4.36 ± 0.10 44 
6 > -4 >100 
7 > -4 >100 
8 > -4 >100 
9 > -4 >100 
10 -4.22 ± 0.06 60 
11 > -4 >100 
12 > -4 >100 
13 -4.10 ± 0.31 80 
14 -4.20 ± 0.12 64 
aFor structures, see Figures 2 and 6. 






Figure 2. Structures of (A) the lead cyclopentapeptide 2, (B) the tripeptidic compounds 3–4, 
and (C) the macrocyclic compounds 5–10. 
 
2.3. Design and SAR. 
2.3.1. Linear Tripeptidic Compounds. 
Taking a minimalist approach, 2 was initially dissected to the linear peptidic derivative 3 
(Figure 2B) in order to determine the activity of the isolated Arg1-Arg2-2-Nal3 motif. The N-
acetylated D-Arg1-Arg2-2-Nal3 tripeptide amide 4 (Figure 2B) was also included to study the 
role of the two flanking amide groups. Compound 3 (EC50 = 58 µM) displayed 112-fold 
lower potency than 2, reflecting the extensive dissection of the cyclopentapeptide structure. 
This finding is consistent with literature data for similar linear tripeptidic CXCR4 antagonists 
originating from an Arg-Arg-Nal motif;16,17 representative structures are shown in Figure 3. 
In the same way as 3, these compounds were based on a central L-arginine, and were found to 
have moderate potency (anti-HIV assay), typically in the order of 100-fold reduction relative 
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Figure 3. Structures of previously reported linear tripeptidic CXCR4 antagonists.16,17 
 
The N- and C-terminal capped linear tripeptide 4 showed somewhat lower activity (EC50 = 86 
µM) than 3; thus, the terminal amide groups of 4 do not contribute favorably to activity. The 
activity of 4 relative to 2 (165-fold reduction) is consistent with SAR studies by Fujii et al. 
which showed that the linear N- and C-terminal capped pentapeptide Ac-D-Arg1-L-Arg2-L-2-
Nal3-Gly4-D-Tyr5-NH2 was 173-fold less potent (anti-HIV assay) than the parent 
cyclopentapeptide 2.5 
 
2.3.2. Macrocyclic Compounds. 
The analogs 3 and 4 are quite flexible, which is generally considered as an undesirable 
feature, and a macrocyclic constraint was reintroduced to force the D-Arg1-Arg2-2-Nal3 motif 
into a more restricted conformation (Figure 2C). Use of a Gly4-Gly5 dipeptide spacer to give 
a simplified cyclopentapeptide (5) resulted in a slight increase in potency (EC50 = 44 µM) 
relative to 4. Since the Gly4-Xaa5 amide bond was not found to be involved in direct binding 
interactions with the receptor in our recently proposed binding mode,11 5 was further 
simplified by replacing Gly4-Gly5 with a 5-aminopentanoic acid4 hydrocarbon spacer (6). 
This modification, which essentially is an ethylene amide bond isostere (Ψ[CH2CH2]) 
replacement, resulted in loss of activity in our assay (EC50 > 100 µM). This shows that the 
planar and polar Gly4-Gly5 amide bond in 5 contributes favorably to activity, either by 












Narumi et al.17 
compd 26:
EC50 = 11 µM (FC131 = 0.16 µM)
Tamamura et al.16
compd 39 (ST34): 
IC50 > 1.0 µM (FC131 = 0.0032 µM)














Next, we employed a ring expansion/contraction strategy by using ω-amino carboxylic acid 
spacers of different length (7–10, Figure 2C). Extension of the hydrocarbon spacer in 6 (15-
membered ring) to give a 16-membered ring (7) or contraction to give a 14-membered ring 
(8) did still not give any measurable activity (EC50 > 100 µM for both compounds). Similarly, 
the 13-membered ring (9) was inactive (EC50 > 100 µM); however, the further constrained 
cyclotetrapeptide 10 (12-membered ring) was equipotent (EC50 = 60 µM) with the linear 
tripeptidic compound 3. 
 
2.3.3. Bicyclic Tripeptidomimetics. 
Encouraged by the activity of 10, we set out to develop a further constrained turn-mimicking 
scaffold capable of presenting the side chains and backbone of the D-Arg1-Arg2-2-Nal3 
fragment of the cyclopentapeptide 2 in the required 3D-orientation. The key to successful 
development of such topographical peptidomimetics is knowledge of the bioactive 
conformation of the parent peptide, in this case the cyclopentapeptide ligands. Based on an 
extensive exploration of the conformational space for a series of cyclopentapeptide CXCR4 
antagonists from the literature, we have previously reported a 3D pharmacophore model that 
describes the spatial arrangement of the pharmacophoric side chains as well as the bioactive 
conformation of the cyclopentapeptide backbone.18 
 
Searching through the extensive literature on turn-mimetics (see ref 19 for a review), we were 
intrigued by the tripeptide-derived 3,6,8-trisubstituted20 bicyclic structure A (Figure 4A),21,22 
which contains two endocyclic amide bonds. The synthesis of A was first reported by 
Vojkovsky et al. who suggested it as a potential peptide-turn motif;21 however, no biological 
applications of A have yet been reported. In order to elucidate whether this scaffold would be 
suitable for our purpose, a structural comparison of low-energy conformations of A with our 
3D pharmacophore model was undertaken. This showed that scaffold A is able to orient the 























Figure 4. (A) Structure of scaffold A, and (B) superimposition of a low-energy conformation 
of A (grey carbon atoms) and the bioactive backbone conformation of the cyclopentapeptide 
CXCR4 antagonists (green carbon atoms) as defined by our 3D pharmacophore model.18 
RMSD = 0.160 Å (cf. section 4.2). 
 
Scaffold A contains three stereocenters, where two (C3 and C6) are defined by the building 
blocks (see Scheme 4 in Chemistry section). The bridge-head stereocenter (C9a) is formed in 
the final cyclization step, and the stereochemical outcome has been shown to be governed by 
the configuration at C3 (see Chemistry section);23 thus, two diastereomeric scaffolds A and 
A’ (Figure 5A) can be prepared. Interestingly, structural comparison of the expected 
bioactive conformation of A (shown in Figure 4B) with low-energy conformations of A’ 
showed that A’ can adopt an almost identical conformation with respect to the orientation of 
the two amide bonds and the three side chains (Figure 5B). 
 
 
Figure 5. (A) Structures of the diastereomeric scaffolds A and A’, and (B) superimposition 
of low-energy conformations of A (grey carbon atoms) and A’ (green carbon atoms). RMSD 
= 0.036 Å (cf. section 4.2). 
 
Thus, we decided to pursue tripeptidomimetic compounds 11 and 12 (based on scaffold A 
and A’, respectively; Figure 6) by using L- and D-cysteine as building blocks, resulting in an 
amide group in the R1 side chain. In order to introduce the same arginine R1 side chain as the 
parent cyclopentapeptide, we also adapted the synthesis to allow for preparation of 13 and 14 





























Figure 6. Structures of the bicyclic target compounds 11–14. 
 
Interestingly, compounds 11 and 12 were inactive, while compounds 13 and 14 (EC50 = 80 
and 64 µM, respectively) showed activity similar to 3 and 10. Clearly, the amide bond in the 
R1 side-chain of 11 and 12 is unfavorable for the biological activity, an observation that 
justifies the synthetic effort put into the R1 building block 33 that was used for 13 and 14 (see 
Scheme 7, Chemistry section). Thus, 13 and 14 represent new peptidomimetic hit compounds 
for CXCR4 antagonism. 
 
The scaffold-based tripeptidomimetics 13 and 14 are significantly less potent (154- and 123-
fold, respectively) than the optimized cyclopentapeptide 2 that they are based on. This was an 
expected consequence of the rather extensive structural changes that were needed in order to 
arrive at downsized structures. To our knowledge, there are only two other examples of 
scaffold-based tripeptidomimetic CXCR4 antagonists in the literature (Figure 7): Niida et al. 
used a 1,3,6-trisubstituted 1,6-dihydropyridin-2-one scaffold,24 while Ueda et al. have 
reported a series of achiral CXCR4 antagonists based on a 1,2,5-trisubstituted indole 
scaffold.25 Also for these compounds, a significant drop in activity compared to the parent 
cyclopentapeptides was observed; the same group has typically reported an IC50-value of 
0.008 µM for the cyclopentapeptide 2, which means that the affinity reduction for the 
dihydropyridin-2-one based compound (IC50 = 15.1 µM) and the indole-based compound 
(IC50 = 3.0 µM) was 1888- and 375-fold, respectively. These numbers reflect the general 























































Figure 7. Structures of previously reported scaffold-based tripeptidomimetic CXCR4 
antagonists.24,25 
 
The moderate activity of our prototype bicyclic tripeptidomimetics 13 and 14 also means that 
binding mode studies (typically performed by combining site-directed receptor mutagenesis 
studies and molecular docking) are not expected to provide reliable data for these 
compounds. Thus, further SAR studies, aimed at optimizing both the scaffold core and the 
side chains, are currently in progress. 
 
2.4. Chemistry. 
The macrocyclic compounds 2 and 5–10 were prepared by head-to-tail macrolactamization of 
linear precursors (Scheme 1) that were obtained through Fmoc-based solid phase peptide 
synthesis (SPPS). The linear precursors were prepared using either a preloaded Fmoc-Gly 
trityl resin (2, 5, and 10) or a 2-chlorotrityl chloride resin for the loading of the N-Fmoc ω-
aminocarboxylic acids (6–9). Cleavage from the resin was facilitated using 
hexafluoroisopropanol and the side-chain protected peptides were cyclized using PyBOP 






























Scheme 1. Synthesis of 2 and 5–10. Reagents and conditions: (a) N-Fmoc ω-amino-
carboxylic acid, DIPEA, CH2Cl2, rt, 1 h; (b) MeOH, DIPEA, CH2Cl2, rt, 2 x 5 min (c) HFIP, 
CH2Cl2, rt, 15 min, then 2 x 10 min; (d) PyBOP, DIPEA, DMF/CH2Cl2, rt, 24 h; (e) 
TFA/TIS/H2O, rt, 2 h. 
 
Compound 3 was synthesized (Scheme 2) by coupling protected arginine 15 with 2-
(naphthalene-2-yl)ethanamine to give 16, which in turn was Fmoc-deprotected and coupled 
with N-Boc 5-aminopentanoic acid to give 17. Global deprotection facilitated by TFA 
followed by guanidinylation of the primary amine gave 3. 
 
  
Scheme 2. Synthesis of 3. Reagents and conditions: (a) 2-(naphthalene-2-yl)ethanamine 
hydrochloride, HBTU, DIPEA, DMF, rt, 20 h; (67%); (b) 2-ethanolamine, DMF, rt, 3 h; (c) 
N-Boc 5-aminopentanoic acid, HATU, DIPEA, DMF, 24 h; (d) TFA/TIS/H2O, rt, 2 h; (e) 
1H-pyrazole-1-carboxamidine hydrochloride, DIPEA, DMF, rt, 48 h (21% over four steps). 
 
The linear tripeptide 4 was prepared by Fmoc-based SPPS on an Fmoc-NH-Rink amide resin 
(Scheme 3) followed by acetylation of the N-terminal using acetic anhydride. Cleavage from 




































Scheme 3. Synthesis of 4. Reagents and conditions: (a) Ac2O, DIPEA, DMF, rt, 30 min; (b) 
TFA/TIS/H2O, rt, 3 h. 
 
The key step in the synthesis of the bicyclic tripeptidomimetics 11–14 (Scheme 4) is the 
spontaneous formation of the 6,6-fused bicyclic ring system A upon treatment of acetal C 
with TFA.21,22 The resulting aldehyde condensates with the backbone amide nitrogen to give 
the N-acyliminium ion intermediate B, which subsequently undergoes nucleophilic attack 
from the deprotected thiol, resulting in the formation of the desired bicycle A.21,22 The 
cyclization occurs stereoselectively,23 and the configuration at the bridge-head (C9a) is 
dependent on the configuration at C3 (R1 substituent), and in the absence of a R1 substituent 
on the configuration at C6. 
 
Scheme 4. Scaffold and retrosynthetic strategy. 
 
Synthesis of the linear precursor C requires access to the three building blocks D, E and F. 
For the synthesis of target compounds 11 and 12, the R1-side chain (incorporated through 
building block F) was introduced as guanidinylated glycine 20 (Scheme 5). This material was 
prepared by guanidinylation of glycine methyl ester hydrochloride (18) using N,N-di-Boc-
1H-pyrazole-1-carboxamidine followed by hydrolysis of the methyl ester of the resulting 19 
using LiOH in a mixture of water and acetone.26,27  
 
 
Scheme 5. Synthesis of carboxylic acid 20. Reagents and conditions: (a) N,N-di-Boc-1H-
pyrazole-1-carboxamidine, DIPEA, DMF, rt, 14 h (85%); (b) LiOH, H2O/acetone, rt, 1.5 h 
(99%). 
 
Synthesis of the bicyclic core (Scheme 6) commenced with the alkylation of 2-(naphthalene-
2-yl)ethanamine (21) with bromoacetaldehyde dimethyl acetal in refluxing THF to give 
FmocHN 4






















































secondary amine 22. This amine was in turn coupled with protected arginine (15) to give 23 
in high yield. Further Fmoc-deprotection and coupling with appropriately protected L-
cysteine gave 24, which was submitted to another Fmoc-deprotection and then coupled with 
carboxylic acid 20 to give the linear precursor 25. This material was treated with TFA, 
thioanisole and water to facilitate global deprotection, leading to formation of the 
acyliminium ion intermediate that after nucleophilic attack by the thiol gave 11. The 
diastereomeric 12 was prepared by coupling of Fmoc-D-Cys(Trt)-OH to Fmoc-deprotected 
23 to give intermediate 26 (see Experimental section), which in turn was converted to linear 
precursor 27 followed by deprotection and cyclization to give 12.  
 
 
Scheme 6. Synthesis of the bicyclic tripeptidomimetic 11. Reagents and conditions: (a) 
BrCH2CH(OMe)2, THF, reflux, 24 h (30%); (b) Fmoc-Arg(Pbf)-OH (15), HATU, DIPEA, 
DMF, rt, 16 h (83%); (c) Et2HN, CH2Cl2, rt, 2 h; (d) Fmoc-L-Cys(Trt)-OH, HATU, DIPEA, 
CH2Cl2, rt, 22 h (49% over two steps); (e) Et2HN, CH2Cl2, rt, 2 h; (f) 20, HATU, DIPEA, 
CH2Cl2, rt, 18 h (57% over two steps); (g) TFA/thianisole/H2O, rt, 2.5 h (13% after HPLC 
purification). 
 
The configuration of the newly formed stereocenters at the bridge-head carbon atoms (C9a) 
in 11 and 12 (see Figure 5) was determined using the 2D 1H ROESY experiment (see 
supplementary data for detailed ROESY spectra for 11 and 12). The known configurations of 
C6 (S for both 11 and 12) and C3 (R for 11 and S for 12) were used as prerequisites for 
determination of the configuration of C9a. The strong cross-peaks observed at δ 5.09/4.71 
(H9a/H3), δ 5.09/1.73 (H9a/Hβ arginine R2) and the medium strong cross-peak at δ 5.09/1.44 















































configuration of C9a in 11. Moreover, the strong cross-peak observed at δ 5.00/4.72 
(H9a/H3) in the 2D ROESY spectrum of 12 and the presence of only very weak cross-peaks 
at δ 5.00/1.64 (H9a/Hβa arginine R2) and δ 5.00/1.52 (H9a/Hβb arginine R2) confirmed the 
(R) configuration of C9a in 12.  
 
The F building block required for 13 and 14 required a multi-step synthesis (Scheme 7). 2-
Oxopiperidine derivative 28 was selectively reduced using freshly prepared Ca(BH4)2, and 
after an acidic work-up, alcohol 29 was isolated in good yield.28 The alcohol was next taken 
through a carbodiimide-mediated dehydration to give α,β-unsaturated lactam 30.28 Use of N-
(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) in refluxing toluene gave up to 73% 
yield, while DCC gave the product in quantitative yield. In both cases, CuI was added to 
activate the carbodiimide. Next, the lactam was Boc-protected to give 31 followed by 
Michael addition of triphenylmethane thiol to give racemic 32, with excellent yield in both 
steps. Finally, the Boc-protected lactam was hydrolyzed using LiOH to give racemic 
carboxylic acid 33 in high yield. 
 
 
Scheme 7. Synthesis of building block 33. Reagents and conditions. (a) CaCl2, NaBH4, 
MeOH, 0 °C, 2 h, then rt, 16 h (76%); (b) DCC, CuI, toluene, 110 °C, 1 h (quant); (c) Boc2O, 
Et3N, DMAP, CH2Cl2/DMF, rt, 14 h (94%); (d) Ph3CSH, Et3N, CH2Cl2, rt, 14 h (95%); (e) 
1M aq. LiOH, THF, rt, 1 h (94%). 
 
Assembly of the linear precursors for 13 and 14 (Scheme 8) was carried out by Fmoc-
deprotecting 23 and subsequent coupling of the resulting material with carboxylic acid 33, to 
give 34 as an inseparable mixture of diastereoisomers. Linear precursor 34 was globally 




























Scheme 8. Synthesis of 13 and 14. Reagents and conditions. (a) Et2HN, CH2Cl2, rt, 3 h; (b) 
33, HBTU, DIPEA, CH2Cl2, rt, 17 h (85% over two steps); (c) TFA/thioanisole/H2O, rt, 1.5 
h; (d) 1H-pyrazole-1-carboxamidine hydrochloride, DIPEA, DMF, rt, 72 h (7% for 13, 11% 
for 14, over two steps and after HPLC purification). 
 
RP-HPLC analysis after guanidinylation showed two distinct peaks, which were separable by 
semi-prep RP-HPLC. NMR analysis of the two isolated products clearly showed that they 
were single diastereoisomers. For the two isolated products, only the configuration at C6 (S) 
was known, and the configuration of C3 and C9a was determined using the 2D 1H ROESY 
experiment (see supplementary data). For both 13 and 14, strong cross-peaks between H9a 
and H3 (at δ 5.14/2.74 and at δ 4.66/2.38 for 13 and 14, respectively) were observed, 
indicating similar overall geometry to that of 11 and 12. The presence of a cross-peak 
between H9a and Hγ arginine R2 was observed only in the ROESY spectrum of 13 
suggesting that the configuration of C9a for this compound is S, whereas the configuration of 
C9a for the stereoisomer 14 is R. Since H9a and H3 are cis in both 13 and 14, the 
configuration at C3, which stems from the racemic carboxylic acid 33, is R in 13 and S in 14. 
It is interesting to note that S configuration of C9a in 11 and 13 leads to a downfield shift of 
H6 when compared with the analogous R isomer. Grimes et al. speculated that a solvent 
mediated hydrogen bond between the R1-side chain amide NH and the ring carbonyl group 
could contribute to stabilizing a conformation in which the R1 substituent is in an equatorial 
position, which favors the observed stereoselectivity of the cyclization.23 However, for the 
formation of 13 and 14, the absence of a R1 amide NH did not influence on the 
stereoselectivity in the cyclization step. 
 
3. CONCLUSIONS 
In this work we have demonstrated that new scaffold-based tripeptidomimetic CXCR4 
antagonists can be rationally designed from cyclopentapeptide CXCR4 antagonists. The 
bicyclic compounds reported herein represent an interesting class of new tripeptidomimetic 















serve as useful leads for further optimization. The peptidomimetic scaffold we have 
employed is constructed from three building blocks, each containing one of the 
pharmacophoric groups, and therefore allows for synthetic access to a range of target 
molecules. We envision that further SAR studies involving the three different binding groups 
will afford new and optimized CXCR4 antagonists. 
 
4. EXPERIMENTAL SECTION  
 
4.1. Chemistry. 
All reagents and starting materials were purchased from Sigma-Aldrich and used as delivered 
unless otherwise stated. Cyclic peptide 2 was prepared as previously described.13 The 
preparation of 4–10 is described in the supplementary data. Anhydrous toluene, CH2Cl2 and 
THF were obtained from an anhydrous solvent delivery system (SDS-800 from mBraun) at 
the Department of Chemistry, University of Bergen. Analyses using thin layer 
chromatography were performed on Alugram® SIL G/UV254 0.20 mm layer plates from 
Machery-Nagel or on aluminum sheets with Merck silica gel (60 F254). TLC plates were 
visualized using either ultraviolet light or by immersing the plate in 2% solution of ninhydrin 
in ethanol containing 10 drops of concentrated sulphuric acid pr 100 mL followed by heating. 
Purification by flash column chromatography was performed using J.T Baker Silica Gel or 
Merck 60 Kieselgel (230-400 mesh). All final compounds were purified using semi-
preparative RP-HPLC eluting with mixtures of acetonitrile and H2O (both containing 0.1% 
TFA). Fractions of equal purity were pooled and lyophilized. All tested compounds were 





HBTU (945 mg, 2.4 mmol) and DIPEA (0.66 mL, 3.7 mmol) were added to a stirred solution 
of Fmoc-Arg(Pbf)-OH (809 mg, 1.2 mmol) in dry DMF (3 mL) under an argon atmosphere. 
The mixture was stirred at room temperature for 30 min before a solution of 2-(naphthalen-2-
yl)ethan-1-amine hydrochloride (518 mg, 2.5 mmol) in DMF (2 mL) was added drop-wise to 
the reaction mixture, and stirring continued for 20 h. The solvent was evaporated and the 
residue was partitioned between EtOAc (20 mL) and H2O (10 mL). The organic phase was 
washed with H2O (2 x 10 mL), 5% KHCO3 (20 mL) and brine (20 mL), dried over MgSO4, 
	  
18 
filtered and evaporated. The crude product was purified by flash chromatography on silica 
gel (EtOAc/hexane; gradient 1:1 to 9:1) to give the title compound as a white solid (706 mg, 
67%). Rf (EtOAc/hexane 9:1) = 0.23; 1H NMR (400 MHz, CDCl3) δ = 7.75 – 7.67 (m, 5H), 
7.60 – 7.49 (m, 3H), 7.41 – 7.32 (m, 4H), 7.31 – 7.26 (m, 2H), 7.26 – 7.23 (m, 1H), 4.34 – 
4.20 (m, 2H), 4.17 – 4.06 (m, 2H), 3.66 – 3.45 (m, 2H), 3.24 – 3.08 (m, 2H), 2.97 – 2.92 (m, 
2H), 2.90 – 2.87 (m, 2H), 2.81 – 2.79 (m, 2H), 2.53 (s, 3H), 2.46 (s, 3H), 2.05 (s, 3H), 1.48 – 
1.40 (m, 8H); 13C NMR (101 MHz, CD3OD) δ = 174.9, 173.4, 165.3, 160.3, 158.67, 158.66, 
158.4, 145.7, 145.5, 143.0, 143.0, 139.9, 138.3, 135.4, 134.1, 134.0, 129.5, 129.20, 129.18, 
129.0, 128.78, 128.74, 128.6, 127.4, 126.8, 126.6, 126.5, 121.3, 118.9, 88.1, 68.2, 62.0, 56.6, 
44.3, 42.0, 39.3, 37.4, 36.9, 32.1, 30.9, 29.0, 21.3, 20.0, 18.8, 14.9, 13.0; HRMS (ESI): m/z 




To a solution of the Fmoc-protected amine 16 (610 mg, 0.77 mmol) in DMF (6 mL) was 
added 2-ethanolamine (6 mL) and the mixture was stirred for 3 h at room temperature under 
HPLC monitoring. The solvent was removed in vacuo, the residue was dissolved in EtOAc, 
washed with H2O (2 x 10 mL), saturated NaHCO3 (2 x 10 mL) and brine (15 mL). The 
solvent was evaporated and the crude product (500 mg) was used in the next step without 
further purification. HRMS (ESI): m/z [M + H]+ calcd for C31H41N5O4S: 580.2952; found: 
580.2958. 
HATU (590 mg, 1.5 mmol) and DIPEA (0.41 mL, 2.3 mmol) were added to a stirring 
solution of 5-((tert-butoxycarbonyl)amino)pentanoic acid (338 mg, 1.5 mmol) in dry DMF (3 
mL) under an argon atmosphere. The mixture was stirred at room temperature for 30 min 
before a solution of the crude product from the previous step (451 mg, 0.78 mmol) in DMF 
(1.5 mL) was added drop wise to the reaction mixture, and stirring continued for 24 h. The 
reaction mixture was partitioned between EtOAc (30 mL) and H2O (20 mL). The aqueous 
layer was extracted with EtOAc (2 x 15 mL) and the combined organic layer washed with 
10% citric acid (15 mL), 5% KHCO3, (15 mL) and brine (15 mL), and dried over MgSO4. 
Filtration and removal of the solvent under reduced pressure gave the crude product (520 
mg). Purification by flash chromatography (EtOAc/hexane; gradient 1:1 to pure EtOAc, 
followed by EtOAc/MeOH; gradient 9:1 to 8:2) afforded 17 as colorless foam (358 mg) 
which was judged to be of sufficient purity for the next step. HRMS (ESI): m/z [M + H]+ 
calcd for C41H59N6O7S: 779.4160; found: 779.4168. 
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The Boc-protected amine 17 (358 mg, 0.46 mmol) was dissolved in a mixture of TFA, TIS 
and H2O (95:2.5:2.5, 15 mL) and the resulting solution was stirred at room temperature. The 
reaction was monitored using analytical RP-HPLC and all starting material was found to be 
consumed after 2 h. The TFA solution was evaporated and the residue was precipitated by 
addition of cold diethyl ether (10 mL) and cooled overnight. The ether was decanted and the 
residue was dried in vacuo to give the crude product (403 mg), which was used in the next 
step without further purification. HRMS (ESI): m/z [M + H]+ calcd for C23H34N6O2: 
427.2816; found: 427.2816. 
To a stirring solution of the crude primary amine (403 mg, 0.61 mmol) in DMF (3 mL) was 
added 1H-pyrazole-1-carboxamidine hydrochloride (453 mg, 3.0 mmol) and DIPEA (0.53 
mL, 3.1 mmol) and the resulting mixture was stirred under nitrogen atmosphere for 48 h. The 
reaction was monitored using analytical RP-HPLC. After the solvent had been evaporated, 
the residue was precipitated by addition of cold diethyl ether, washed with ether, purified by 
preparative RP-HPLC, and lyophilized (129 mg, 21% over four steps). 1H NMR (400 MHz, 
CD3OD): δ = 7.59 – 7.51 (m, 3H), 7.42 (s, 1H), 7.24 – 7.10 (m, 3H), 4.01 (dd, J = 8.3, 5.7, 
1H), 3.39 – 3.23 (m, 2H), 2.90 (t, J = 6.7, 2H), 2.80 (m, 2H), 2.73 (t, J = 7.0, 2H), 2.00 (t, J = 
7.0, 2H), 1.51 – 1.09 (m, 8H); 13C NMR (101 MHz, CD3OD): δ = 175.9, 174.3, 158.84, 
158.81, 138.0, 135.2, 133.9, 129.3, 128.8, 128.7, 128.54, 128.48, 127.2, 126.6, 54.7, 42.2, 
42.0, 41.8, 36.7, 36.1, 30.4, 29.5, 26.4, 23.8; HRMS (ESI): m/z [M + H]+ calcd for 
C24H36N8O2: 469.3034; found: 469.3033. 
 
4.1.3. Methyl (N,N'-bis(tert-butoxycarbonyl)carbamimidoyl)glycinate (19)26 
To a slurry of glycine methyl ester hydrochloride (1.11 g, 8.8 mmol) in DMF (30.5 mL) was 
added N,N-di-Boc-1H-pyrazole-1-carboxamidine (1.02 g, 3.3 mmol) and DIPEA (1.1 mL, 6.3 
mmol). The mixture was stirred overnight (14 h) at room temperature and turned into a 
yellow slurry. The reaction mixture was partitioned between EtOAc (25 mL) and H2O (20 
mL) and the aqueous layer was further extracted three times with EtOAc (25 mL), before the 
combined organic layers were dried over anhydrous MgSO4. The solvent was evaporated 
under reduced pressure to give the crude product as a light yellow solid (1.4 g). Further 
purification using flash column chromatography (Hexanes/EtOAc, 3:1) gave the title 
compound as a colourless solid (932 mg, 85 %). Rf (Hexanes/EtOAc, 3:1) = 0.27; 1H NMR 
(400 MHz, CDCl3) δ = 11.44 (s, 1H), 8.87 (s, 1H), 4.25 (d, J = 4.9, 2H), 3.78 (s, 3H), 1.51 (s, 
9H), 1.50 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 170.2, 163.6, 156.3, 153.3, 83.7, 79.9, 
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52.8, 43.0, 28.6, 28.4; HRMS (ESI): m/z [M + H]+ calcd for C14H26N3O6: 332.1822; found: 
332.1821. 
 
4.1.4. (N,N'-bis(tert-Butoxycarbonyl)carbamimidoyl)glycine (20)27 
LiOH·H2O (166 mg, 4.0 mmol) was added to a solution of methyl ester 19 (330 mg, 1 mmol) 
in acetone/H2O (6:1, 4.5 mL) at room temperature. TLC monitoring showed full consumption 
of the starting material after 1.5 h, and the reaction mixture was cooled to 0 °C before a 0.5 
M aqueous HCl solution was added drop-wise until pH 3. The mixture was allowed to warm 
to room temperature and extracted with EtOAc (3 x 20 mL). Drying over anhydrous Na2SO4 
and evaporation of the solvent gave the title compound as a colourless solid (312 mg, 99 %). 
Rf (Hexanes/EtOAc/AcOH, 60:40:1) = 0.20; 1H NMR (400 MHz, CDCl3) δ = 11.37 (s, 1H), 
8.87 (s, 1H), 4.18 (s, 2H), 1.51 (s, 9H), 1.49 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 171.7, 
162.2, 157.0, 153.1, 84.4, 80.9, 44.3, 28.5, 28.3; HRMS (ESI): m/z [M + H]+ calcd for 
C13H23N3O6: 318.1665; found: 318.1657. 
 
4.1.5. 2,2-Dimethoxy-N-(2-(naphthalen-2-yl)ethyl)ethan-1-amine (22) 
2-(Napthalene-2-yl)ethyl-1-amine (21) (322 mg, 1.9 mmol) and bromoacetataldehyde 
dimethyl acetal (0.2 mL, 1.7 mmol) were dissolved in dry THF (4 mL), and the mixture was 
heated at a gentle reflux for 24 h. After the solvent was evaporated, the residue was dissolved 
in CH2Cl2 (20 mL) and the organic phase was washed with saturated NaHCO3 (2 x 10 mL) 
and brine. The mixture was concentrated and purified by flash chromatography on silica gel 
(EtOAc) to give the title compound (130 mg, 30%) as yellow oil. Rf (EtOAc) = 0.14; 1H 
NMR (400 MHz, CDCl3): δ = 7.78 (t, J = 8.6, 3H), 7.64 (s, 1H), 7.49 – 7.37 (m, 2H), 7.33 (d, 
J = 8.4, 1H), 4.45 (t, J = 5.4, 1H), 3.34 (s, 6H), 2.96 (s, 4H), 2.78 (d, J = 5.4, 2H); 13C NMR 
(100 MHz, CDCl3): δ = 137.7, 133.8, 132.4, 128.3, 127.9, 127.7, 127.5, 127.2, 126.2, 125.5, 






HATU (183 mg, 0.48 mmol) and DIPEA (84 µL, 0.48 mmol) were added to a stirred solution 
of Fmoc-Arg(Pbf)-OH (292 mg, 0.45 mmol) in dry DMF (1.2 mL) under an argon 
atmosphere. The mixture was stirred at room temperature for 30 min before amine 22 (125 
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mg, 0.48 mmol) in DMF (0.6 mL) was added drop-wise to the reaction mixture, and stirring 
continued for 16 h. The reaction mixture was partitioned between H2O (10 mL) and EtOAc 
(20 mL). The organic phase was further washed with H2O (2 x 10 mL) and brine (2 x 10 mL), 
dried over MgSO4, filtered and evaporated. The crude product was purified by flash 
chromatography on silica gel (EtOAc/hexane 8.5:1.5) to give the title compound as white 
foam (334 mg, 83 %, retains EtOAc). Rf (EtOAc/hexane 8.5:1.5) = 0.28; 1H NMR and 13C 
NMR gave no useful information due to rotamers; HRMS (ESI): m/z [M + H]+ calcd for 
C50H60N5O8S: 890.4157; found: 890.4166; m/z [M + Na]+ calcd for C50H59N5O8SNa: 






Et2NH (1.5 mL) was added to a solution of the Fmoc-protected amine 23 (261 mg, 0.29 
mmol) in CH2Cl2 (3 mL) and the mixture was stirred at room temperature for 2 h with TLC 
monitoring. The solvent was removed under reduced pressure, to give a light yellow foam. 
The crude product (230 mg) was used directly in the next step. 
To a solution of crude Fmoc-deprotected 23 (0.29 mmol) in CH2Cl2 (2 mL), were added 
Fmoc-Cys(Trt)-OH (183 mg, 0.31 mmol), HATU (112 mg, 0.30 mmol) and DIPEA (0.14 
mL, 0.8 mmol), and the mixture was stirred for 22 h at room temperature. After evaporation 
of the solvent, the residue was partitioned between EtOAc (15 mL) and H2O (50 mL). The 
aqueous layer was extracted with EtOAc (2 x 15 mL), and the combined organic layer was 
washed with 1M KHSO4 (30 mL), H2O (30 mL), saturated NaHCO3 (30 mL), brine (30 mL) 
and was dried over anhydrous MgSO4. Removal of the solvent under reduced pressure gave 
the crude product as an orange colored foam (419 mg). Purification by flash column 
chromatography (EtOAc/hexanes, 8:2) gave 24 as a colorless foam (194 mg, 49 % over 2 
steps). 1H NMR showed that the product retained EtOAc, and the yield is adjusted 
accordingly. Rf (EtOAc/hexane, 8:2) = 0.16; 1H NMR and 13C NMR gave no useful 
information due to rotamers; HRMS (ESI): m/z [M + Na]+ calcd for C72H78N6O9S2Na: 








Et2NH (0.73 mL) was added to a solution of the Fmoc-protected amine 24 (181 mg, 0.15 
mmol) in CH2Cl2 (1.5 mL) at room temperature. TLC monitoring showed no sign of the 
starting material after 2 h and the solvent was removed under reduced pressure to give a light 
yellow foam. The crude product (183 mg) was used directly in the next step. HRMS (ESI): 
m/z [M + H]+ calcd for C57H69N6O7S2: 1013.4669; found: 1013.4672. 
To a solution of carboxylic acid 20 (183 g, 0.31 mmol) in CH2Cl2 (1 mL), were added HATU 
(60 mg, 0.16 mmol), DIPEA (0.07 mL, 0.40 mmol) and Fmoc-deprotected 24 (65 mg, 0.2 
mmol) and the resulting yellow reaction mixture was allowed to stir for 18 h at room 
temperature. The solvent was evaporated and the residue was partitioned between EtOAc (10 
mL) and H2O (10 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL), and the 
combined organic layer was washed with 1M KHSO4 (20 mL), H2O (20 mL), saturated 
NaHCO3 (20 mL), brine (20 mL) and was dried over anhydrous MgSO4. Removal of the 
solvent under reduced pressure gave the crude product as a yellow foam (203 mg). 
Purification by flash column chromatography (EtOAc/hexanes, 9:1) gave the title compound 
as a light yellow foam (101 mg, 57 % over 2 steps). 1H NMR showed that the product 
retained EtOAc, and the yield is adjusted accordingly. Rf (EtOAc/hexanes, 9:1) = 0.21; 1H 
NMR and 13C NMR gave no useful information due to rotamers; HRMS (ESI): m/z [M + H]+ 




Linear precursor 25 (92 mg, 0.07 mmol) was dissolved in a mixture of TFA, thioanisole and 
distilled H2O (90:5:5, 8 mL) and stirred for 2.5 h at room temperature. After evaporation of 
the solvent under reduced pressure the brown residue was cooled to 0 °C. Addition of cold 
ether resulted in precipitation and the crude solid was purified by preparative RP-HPLC, and 
lyophilized to give 11 as a fluffy white solid (7.2 mg, 13%). 1H NMR (600 MHz, CD3OD): δ 
= 7.82 – 7.79 (m, 3H), 7.70 (s, 1H), 7.47 – 7.41 (m, 3H), 5.09 (dd, J = 7.4, 4.0, 1H), 4.95 (dd, 
J = 9.3, 6.1, 1H), 4.71 (t, J = 8.8, 1H), 4.03 – 3.97 (m, 3H), 3.81 (dd, J = 13.3, 7.5, 1H), 3.64 
(dd, J = 13.4, 4.0, 1H), 3.53 (m, 1H), 3.11 – 3.01 (m, 6H), 1.79 – 1.66 (m, 2H), 1.48 – 1.40 
(m, 2H); 13C NMR (150.9 MHz, CD3OD) δ = 170.0, 169.6, 168.9, 159.5, 158.5, 137.3, 135.1, 
133.9, 129.3, 128.7, 128.5, 128.44, 128.40, 127.2, 126.7, 57.3, 52.27, 52.26, 51.4, 49.5, 44.7, 
41.6, 34.4, 29.8, 27.1, 26.3; HRMS (ESI): m/z [M + 2H]2+ (z = 2) calcd for C26H37N9O3S: 
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Et2NH (7 mL) was added to a solution of the Fmoc-protected amine 23 (308 mg, 0.33 mmol) 
in CH2Cl2 (7 mL) and the reaction was stirred for 3 h at room temperature with HPLC 
monitoring. The solvent was removed under reduced pressure and the crude product (320 
mg) was used directly in the next step. HRMS (ESI): m/z [M + H]+ calcd for C35H50N5O6S: 
668.3476; found: 668.3488. 
Fmoc-D-Cys(Trt)-OH (364 mg, 0.62 mmol), HATU (236 mg, 0.62 mmol) and DIPEA (0.25 
mL, 1.4 mmol) were dissolved in CH2Cl2 (2 mL) and the resulting mixture was stirred for 30 
min at room temperature, before a solution of crude Fmoc-deprotected 23 (320 mg, 0.48 
mmol) in CH2Cl2 (3 mL) was added. The reaction mixture was stirred for 24 h at room 
temperature under anhydrous conditions (CaCl2). After evaporation of the solvent the residue 
was partitioned between EtOAc (20 mL) and H2O (40 mL). The aqueous layer was extracted 
with EtOAc (2 x 15 mL), and the combined organic layer was washed with 1M KHSO4 (30 
mL), H2O (30 mL), saturated NaHCO3 (30 mL), brine (30 mL) and was dried over anhydrous 
MgSO4. Removal of the solvent under reduced pressure gave the crude product as a light red 
colored foam (710 mg). Purification by flash column chromatography (EtOAc/hexanes, 8:2) 
gave the title compound as a colorless foam (237 mg, 45% over two steps). Rf 
(EtOAc/hexane, 8:2) = 0.19; HRMS (ESI): m/z [M + H]+ calcd for C72H78N6O9S2: 






Et2NH (6 mL) was added to a solution of the Fmoc-protected amine 26 (237 mg, 0.19 mmol) 
in CH2Cl2 (6 mL) and the reaction was stirred for 3 h at room temperature with HPLC 
monitoring. The solvent was removed under reduced pressure and the crude product (277 
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mg), was used directly in the next step. HRMS (ESI): m/z [M + H]+ calcd for C57H69N6O7S2: 
1013.4664; found: 1013.4663 
To a solution of carboxylic acid 20 (150 mg, 0.47 mmol) in CH2Cl2 (2 mL), were added 
HATU (156 mg, 0.41 mmol) and DIPEA (0.15 mL, 0.82 mmol). The mixture was stirred at 
room temperature under anhydrous environment (CaCl2) for 15 min before a solution of the 
Fmoc-deprotected amine 26 (277 mg, 0.27 mmol) in CH2Cl2 (2 mL) was added drop-wise to 
the reaction mixture, and stirring continued for 24 h. After evaporation of the solvent the 
residue was partitioned between EtOAc (20 mL) and H2O (30 mL). The aqueous layer was 
extracted with EtOAc (2 x 15 mL), and the combined organic layer was washed with 1M 
KHSO4 (30 mL), H2O (30 mL), saturated NaHCO3 (30 mL), brine (30 mL), and was dried 
over anhydrous MgSO4. Removal of the solvent under reduced pressure gave the crude 
product (352 mg). Purification by flash column chromatography (EtOAc/hexanes, 9:1) gave 
the title compound (93 mg, 37% over 2 steps). Rf (EtOAc/hexane, 9:1) = 0.45; NMR analyses 
did not give useful information due to formation of rotamers; HRMS (ESI): m/z [M + H]+ 




Linear precursor 27 (76 mg, 0.06 mmol) was dissolved in a mixture of TFA, thioanisole and 
distilled H2O (90:5:5, 7 mL) and stirred for 2 h. After evaporation of the solvent under 
reduced pressure the brown residue was cooled to 0 °C. Addition of cold ether resulted in 
precipitation and the crude product was purified by preparative RP-HPLC, and lyophilized to 
give the title compound as a fluffy white solid (1.5 mg, 3%). 1H NMR (600 MHz, CD3OD): δ 
= 7.84 – 7.78 (m, 3H), 7.70 (s, 1H), 7.46 – 7.39 (m, 3H), 5.00 (dd, J = 11.0, 5.4, 1H), 4.72 
(dd, J = 11.9, 6.3, 1H), 4.64 (t, J = 8.0, 1H), 4.15 – 4.08 (m, 1H), 3.99 (q, J = 29.4, 17.3, 2H), 
3.70 – 3.55 (m, 3H), 3.36 (dd, J = 10.6, 6.3, 1H), 3.12 – 3.04 (m, 2H), 3.01 – 2.96 (m, 1H), 
2.90 – 2.85 (m, 1H), 2.73 (t, J = 11.3, 1H), 1.67 – 1.58 (m, 1H), 1.56 – 1.49 (m, 1H), 1.31 – 
1.24 (m, 2H); 13C NMR (150.9 MHz, CD3OD) δ = 170.5, 169.9, 169.3, 159.4, 158.4, 137.2, 
135.0, 133.9, 129.3, 128.7, 128.6, 128.5, 128.4, 127.4, 126.8, 57.6, 52.8, 51.4, 48.9, 48.7, 
44.6, 41.4, 34.7, 30.7, 28.5, 26.3; HRMS (ESI): m/z [M + H]+ calcd for C26H35N9O3S; 






4.1.13. 3-(Hydroxymethyl)piperidin-2-on (29)28 
To a stirred suspension of ethyl 2-oxopiperidine-3-carboxylate (28) (1.00 g, 5.8 mmol) and 
anhydrous CaCl2 (702 mg, 6.3 mmol) in dry MeOH (12 mL) in an ice/H2O bath, NaBH4 (501 
mg, 13 mmol) was added in one portion, and stirring was continued for 2 h at 0 °C. After 16 
h of additional stirring at room temperature, the solvent was evaporated, and a 3N aqueous 
citric acid solution was added in small portions until all solid material was dissolved (pH = 2-
3). The solution was extracted with CH2Cl2 (6 x 50 mL), dried over Na2SO4 and filtered. 
Evaporation of the solvent gave the crude product (643 mg), which was purified by flash 
column chromatography on silica gel (5 % MeOH in EtOAc) to give the title compound as 
white solid (573 mg, 76 %). Rf (EtOAc) = 0.11; 1H NMR (400 MHz, CDCl3): δ = 5.99 (bs, 
1H), 4.07 (d, J = 8.5, 1H), 3.81 – 3.60 (m, 2H), 3.39 – 3.21 (m, 2H), 2.56 – 2.42 (m, 1H), 
1.97 – 1.71 (m, 3H), 1.56 – 1.39 (m, 1H); 13C NMR (100 MHz, CDCl3, 25°C): δ = 176.2, 
64.9, 43.2, 42.0, 24.1, 22.3; HRMS (ESI): m/z [M + H]+ calcd for C6H12NO2: 130.0868; 
found: 130.0850. 
 
4.1.14. 3-Methylenepiperidin-2-one (30)28 
N,N’-Dicyclohexylcarbodiimide (DCC) (346 mg, 1.7 mmol) was added to a stirring solution 
of alcohol 29 (167 mg, 1.3 mmol) in dry toluene (2 mL). The mixture was heated at 110 °C 
(oil bath) and CuI (23 mg, 0.12 mmol) was added and the mixture was stirred for 70 min 
before it was cooled to room temperature, after which H2O (1.6 mL) was added and stirring 
continued for 1 h. Et2O (3.4 mL) was added, and the mixture was filtered. The aqueous phase 
was separated and extracted four times with 30 mL portions of CH2Cl2. The combined 
extracts were dried over K2CO3, filtered and evaporated to give the title compound as a white 
solid (144 mg, 100 %). Rf (EtOAc) = 0.17; 1H NMR (400 MHz, CDCl3): δ = 6.91 (bs, 1H), 
6.21 (bs, 1H), 5.37 – 5.26 (m, 1H), 3.40 (td, J = 6.2, 2.6, 2H), 2.67 – 2.51 (m, 2H), 1.95 – 
1.79 (m, 2H); 13C NMR (100 MHz, CDCl3): δ = 166.6, 138.1, 122.5, 43.2, 30.4, 23.7; HRMS 
(ESI): m/z [M + H]+ calcd for C6H10NO: 112.0762; found: 112.0779. 
 
4.1.15. tert-Butyl 3-methylene-2-oxopiperidine-1-carboxylate (31) 
Et3N (1.2 mL, 8.8 mmol) and DMAP (1.07 g, 8.8 mmol) were added to a stirring solution of 
lactam 30 (971 mg, 8.7 mmol) in dry CH2Cl2/DMF (10:1, 27 mL). Boc2O (3.83 g, 17 mmol) 
in CH2Cl2 (12 mL) was added drop-wise, and the reaction mixture was stirred at room 
temperature for 14 h. The mixture was concentrated and purified by flash column 
chromatography on silica gel (EtOAc/hexane 1:4) to give the title compound (1.72 g, 94 %) 
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as transparent thick oil. Rf (EtOAc/hexane 1:4) = 0.34; 1H NMR (400 MHz, CDCl3): δ = 6.33 
(d, J = 1.4, 1H), 5.41 (d, J = 0.7, 1H), 3.78 – 3.67 (m, 2H), 2.58 (t, J = 6.1, 2H), 1.95 – 1.84 
(m, 2H), 1.55 (s, 9H); 13C NMR (100 MHz, CDCl3): δ = 164.8, 153.3, 138.8, 125.1, 83.1, 
46.9, 29.5, 28.2, 22.8; HRMS (ESI): m/z [M + Na]+ calcd for C11H17NO3Na: 234.1102; 
found: 234.1101. 
 
4.1.16. tert-Butyl 2-oxo-3-(tritylthiomethyl)piperidine-1-carboxylate (32) 
To a stirred solution of lactam 31 (1.65 g, 7.8 mmol) in dry CH2Cl2 (33 mL) was added 
Ph3CSH (2.16 g, 7.8 mmol) and Et3N (1.1 mL, 7.8 mmol) and the resulting mixture was 
stirred at room temperature for 12 h. The reaction mixture was washed with H2O, 
concentrated and purified by flash column chromatography on silica gel (hexane/EtOAc 8:2) 
to give the title compound as white foam (3.60 g, 95 %). Rf (hexane/EtOAc 4:1) = 0.18; 1H 
NMR (400 MHz, CDCl3): δ = δ 7.45 – 7.20 (m, 15H), 3.76 – 3.66 (m, 1H), 3.34 (ddd, J = 
12.9, 7.6, 5.1, 1H), 2.88 (dd, J = 12.7, 4.6, 1H), 2.28 (dd, J = 12.7, 8.6, 1H), 2.09 – 1.97 (m, 
1H), 1.95 – 1.81 (m, 1H), 1.75 – 1.65 (m, 2H), 1.49 (s, 9H), 1.33 – 1.26 (m, 1H); 13C NMR 
(100 MHz, CDCl3): δ = 172.8, 152.9, 145.0, 129.9, 128.1, 126.9, 83.2, 67.1, 45.1, 43.6, 33.0, 
28.2, 25.5, 21.7; HRMS (ESI): m/z [M + Na]+ calcd for C30H33NO3SNa: 510.2073; found: 
510.2070. 
 
4.1.17. 5-(tert-Butoxycarbonylamino)-2-((tritylthio)methyl)pentanoic acid (33) 
To a stirred solution of lactam 32 (3.60 g, 7.4 mmol) in THF (37 mL), was added LiOH (1.0 
M, 15 mL, 15 mmol). The reaction was monitored by TLC and all starting material was 
consumed after 1h. The THF was evaporated and the aqueous residue was acidified to pH 4 
with 10% citric acid. The mixture was extracted with CH2Cl2 (4 x 50 mL), dried over 
MgSO4, filtered and evaporated to give the title compound as white foam (3.52 g, 94%). Rf 
(hexane/EtOAc 6:4) = 0.20; 1H NMR (400 MHz, CDCl3): δ = 7.46 – 7.17 (m, 15H), 4.47 (bs, 
1H), 2.97 (bs, 2H), 2.61 (dd, J = 12.5, 8.1 Hz, 1H), 2.22 (dd, J = 12.6, 6.1 Hz, 1H), 2.11 – 
1.99 (m, 1H), 1.50 – 1.33 (s and m, 11H), 1.26 (m, 2H); 13C NMR (100 MHz, CDCl3): δ = 
179.8, 156.2, 144.8, 129.9, 128.2, 127.0, 79.5, 67.2, 44.9, 40.3, 33.3, 29.0, 28.6, 27.5; HRMS 










Et2HN (1.9 mL, 18 mmol) was added to a stirring solution of 23 (334 mg, 3.8 mmol) in 
CH2Cl2 (3.9 mL) at room temperature. The reaction was monitored by TLC and deemed 
completed after 3 h. The mixture was evaporated to dryness and the residue used in the 
following step. 
To a stirred solution of carboxylic acid 33 (182 mg, 0.36 mmol) in dry CH2Cl2 (2.1 mL), 
were added HBTU (142 mg, 0.38 mmol) and DIPEA (66 µL, 0.38 mmol) and the mixture 
was stirred for 30 min. Fmoc-deprotected amine 23 (250 mg out of 344 mg crude product, 
0.38 mmol) in dry CH2Cl2 (2.1 mL) was added and stirring continued for 17 h. The solvent 
was evaporated to give red foam, which was partitioned between EtOAc (20 mL) and H2O 
(10 mL). The organic phase was separated and washed with 5% KHSO4 (10 mL) and brine 
(10 mL). The organic phase was further concentrated and purified by flash chromatography 
on silica gel (EtOAc/hexane 3:1) to give an inseparable mixture of the two diastereoisomers 
of 34 as white foam (352 mg, 85 %). The product retained EtOAc and the yield is adjusted 
accordingly. Rf (EtOAc/hexane, 3:1) = 0.29; HRMS (ESI): m/z [M + H]+ calcd for 
C65H83N6O9S2: 1155.5658; found: 1155.5667; HRMS (ESI): m/z [M + Na]+ calcd for 




The diastereoisomeric mixture of linear precursor 34 (925 mg, 0.8 mmol) was dissolved in a 
mixture of TFA, thioanisole and H2O (90:5:5, 28 mL) and the resulting mixture was stirred at 
room temperature for 90 min. The TFA mixture was evaporated and the crude product was 
precipitated by addition of cold diethyl ether. The ether was drained off and the residue was 
dried in vacuo to give the crude product as a reddish solid (422 mg). The crude product (210 
mg, approx. 0.43 mmol) in dry DMF (3.5 mL) was added 1H-pyrazole-1-carboxamidine 
hydrochloride (92 mg, 0.63 mmol) and DIPEA (0.11 mL, 0.63 mmol), and the mixture was 
stirred under argon atmosphere for 72 h during which the reaction was monitored by RP-
HPLC. Diethyl ether (30 mL) was then added and the mixture was cooled at 4 °C and stirred 
for an additional hour, resulting in the precipitation of a white solid (230 mg). The crude 
product was purified by preparative HPLC to give the title compound as a fluffy white solid 
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(11 mg, 7%). 1H NMR (600 MHz, CD3OD) δ = 7.82 – 7.77 (m, 3H), 7.69 (s, 1H), 7.47 – 7.40 
(m, 3H), 5.14 (dd, J = 5.4, 4.6, 1H), 4.00 (dt, J = 13.6, 7.7, 1H), 3.70 (dd, J = 13.9, 4.0, 1H), 
3.58 – 3.51 (m, 2H), 3.17 (t, J = 7.0, 2H), 3.10 – 3.98 (m, 5H), 2.78 – 2.73 (m, 1H), 2.58 (t, J 
= 12.0, 1H), 1.91 – 1.85 (m, 1H), 1.68 – 1.56 (m, 4H), 1.46 – 1.41 (m, 1H), 1.40 – 1.35 (m, 
3H); 13C NMR (150.9 MHz, CD3OD) δ = 173.8, 169.4, 158.7, 158.5, 137.3, 135.0, 133.8, 
129.3, 128.7, 128.51, 128.49, 128.45, 127.2, 126.7, 56.6, 52.9, 50.9 (HSQC), 49.3 (HSQC), 
43.8, 42.4, 41.6, 34.4, 30.2, 28.9, 28.6, 27.5, 26.2; HRMS (ESI): m/z [M + H]+ calcd for 




Bicycle 14 was prepared as described for 13. The crude was purified by preparative HPLC to 
give the title compound as a fluffy white solid (16 mg, 11%). 1H NMR (600 MHz, CD3OD) δ 
= 7.84 – 7.80 (m, 2H), 7.78 (d, J = 7.7, 1H), 7.67 (d, 1H), 7.47 – 7.43 (m, 3H), 4.68 – 4.62 
(m, 2H), 4.08 – 4.02 (m, 1H), 3.68 (dt, J = 13.6, 5.9, 1H), 3.60 (d, J = 9.1, 2H), 3.19 – 3.14 
(m, 3H), 3.08 (t, J = 6.7, 2H), 3.00 – 2.95 (m, 1H), 2.94 – 2.90 (m, 1H), 2.55 (t, J = 11.4, 
1H), 2.41 – 2.36 (m, 1H), 1.85 – 1.79 (m, 1H), 1.65 – 1.57 (m, 3H), 1.53 – 1.46 (m, 1H), 1.45 
– 1.39 (m, 1H), 1.33 – 1.25 (m, 2H); 13C NMR (150.9 MHz, CD3OD) δ = 174.1, 170.4, 
158.7, 158.5, 137.3, 134.9, 133.8, 129.3, 128.73, 128.70, 128.42, 128.41, 127.4, 126.8, 57.1, 
53.7, 49.0 (HSQC), 48.9 (HSQC), 42.8, 42.4, 41.5, 34.6, 30.7, 29.9, 28.8, 27.7, 26.3; HRMS 
(ESI): m/z [M + H]+ calcd for C27H39N8O2S: 539.2911; found: 539.2905. 
 
4.2. Molecular modeling. 
The conformational search for scaffolds A and A’ was performed using the MacroModel 
application as integrated in Schrödinger Suite 2012,29 running on a Dell Precision 390 
workstation. The OPLS_2005 force field and the GB/SA solvent model for water were used 
for the energy calculations. The Truncated Newton Conjugate Gradient (TNCG) algorithm 
was used for the energy minimizations, with maximum 500 iterations and a convergence 
threshold of 0.012 kcal/mol×Å (0.05 kJ/mol×Å). The Monte Carlo Multiple Minimum 
(MCMM) search algorithm was used for torsional sampling (1000 steps), and the energy 
cutoff was set to 5 kcal/mol (21 kJ/mol) above the lowest energy conformation. Mirror image 
conformations were retained, and redundant conformations were eliminated by using an 
RMSD cutoff (all atoms) of 0.5 Å. For both scaffolds, this resulted in four low-energy 
conformations, which were superimposed on the backbone of our previously reported 3D 
	  
29 
pharmacophore model for cyclopentapeptide CXCR4 antagonists using five atoms: the α-
carbon atoms of Arg1, Arg2, and 2-Nal3 and the β-carbon atoms of Arg1 and Arg2. 
 
4.3. Biological Studies. 
4.3.1. Transfections and tissue culture. 
COS-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) with Glutamax 
(Invitrogen, UK) supplemented with 10% fetal bovine serum (FBS), 180 units/mL penicillin 
and 45 µg/mL streptomycin (PenStrep) at 37 °C in a 10% CO2/90% humidified atmosphere. 
Transfection of cells was carried out by the calcium phosphate precipitation method.30,31 
Briefly, plasmid DNA (20 µg of receptor cDNA and 30 µg of the chimeric Gαi to Gαq signal-
converting G protein GαΔ6qi4myr) were mixed with TE-buffer (10 mM Tris-HCl, 2 mM 
Na2EDTA, pH 7.5) and 30 µL calcium chloride (2 M) to a total volume of 480 µL, and then 
added to the same amount of HEPES buffered saline (280 mM NaCl, 50 mM HEPES, 1.5 
mM Na2HPO4, pH 7.2). Precipitation was allowed for 45 min at room temperature, after 
which the precipitate together with 300 µL chloroquine (2 mg/mL) in 10 mL culture media 
was added to the 6 × 106 COS-7 cells seeded the day before. Transfection was stopped after 5 
h by replacing media, and cells were incubated overnight. 
 
4.3.2. Functional assay. 
The potency was measured using a scintillation proximity-based inositol-phosphate 
accumulation assay (SPA-IP).32 In brief, one day after transfection COS-7 cells (0.35 × 105 
cells/well) were incubated for 24 h with [3H]-myo-inositol (5 µL/mL, 2 µCi/mL) in 0.1 mL of 
growth medium per well in a 96-well plate. The following day, cells were washed twice in 
PBS and were incubated in 0.1 mL of Hank's balanced salt solution (Invitrogen, U.K.) 
supplemented with 10 mM LiCl at 37 °C in the presence of various concentrations of ligands 
for 90 min. Cells were extracted by addition of 50 µL of 10 mM formic acid to each well, 
followed by incubation on ice for 30−60 min. The [3H]inositol-phosphates in the formic acid 
cell lysates were quantified by Ysi-poly-D-Lys coated SPA beads. Briefly, 35 µL of cell 
extract was mixed with 80 µL of a SPA bead suspension (12.5 µg/µL in H2O) in a PicoPlate-
96 white plate. Plates were sealed, agitated for at least 30 min and centrifuged (5 min, 1500 
rpm). SPA beads were allowed to settle and react with the extract for 8 h before radioactivity 
was determined using a Packard Top Count NXT™ scintillation counter (PerkinElmer, MA, 
USA). All determinations were made in duplicate. This readout has earlier been used 





Experimental procedures for 4–10 and relevant sections of ROESY spectra for compounds 
11–14 can be found in the online version, at http:// 
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ABBREVIATIONS 
2-Nal, L-3-(2-naphthyl)alanine; CXCL12, CXC chemokine ligand 12; CXCR4, CXC 
chemokine receptor 4; DIPEA, N,N-diisopropylethylamine; EDC, N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide; HATU, 1-[bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate; HBTU, 1-[bis(dimethylamino)
methylene]-1H-benzotriazolium-3-oxide hexafluorophosphate; HFIP, 1,1,1,3,3,3-
hexafluoroisopropanol; HOBt, 1-hydroxybenzotriazole; Pbf, 2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-sulfonyl; PyBOP, (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate; SPPS, solid phase peptide synthesis; TIS, triisopropylsilane; Trt, 
triphenylmethyl. 
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